Receive a FREE Mesothelioma Treatment
Information Packet


Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction


Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This is a Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.


Determine the maximum tolerated dose of erlotinib in patients with solid tumors and hepatic or renal dysfunction.
Determine the pharmacokinetics of this drug in these patients.

Location and Contact Information:
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, 94143-0128, United States; Recruiting
Alan Paul Venook, MD 415-476-2201
District of Columbia
Lombardi Cancer Center, Washington, District of Columbia, 20007, United States;
Edward P. Gelmann, MD 202-687-2490

University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States;
Gini F. Fleming, MD 773-702-6712

Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242-1009, United States;
Gerald H. Clamon, MD 319-356-1932

Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, 21201, United States;
Martin J. Edelman, MD 410-328-2703

New Hampshire
Norris Cotton Cancer Center, Lebanon, New Hampshire, 03756-0002, United States; Recruiting
Lionel D. Lewis, MD 603-650-6300

New York
Long Island Jewish Medical Center, New Hyde Park, New York, 11040, United States;
Marc Laurence Citron, MD 718-470-8930

North Shore University Hospital, Manhasset, New York, 11030, United States;
Daniel R. Budman, MD 516-562-8958

North Carolina
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1082, United States;
David Duane Hurd, MD 336-716-2088

Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, 43210-1240, United States;
Clara D. Bloomfield, MD 614-293-7518
Study chairs or principal investigators
Antonius Miller, MD, Study Chair
Comprehensive Cancer Center of Wake Forest University